0001209191-17-027183.txt : 20170417 0001209191-17-027183.hdr.sgml : 20170417 20170417212405 ACCESSION NUMBER: 0001209191-17-027183 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170413 FILED AS OF DATE: 20170417 DATE AS OF CHANGE: 20170417 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kite Pharma, Inc. CENTRAL INDEX KEY: 0001510580 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 2225 COLORADO AVENUE CITY: SANTA MONICA STATE: CA ZIP: 90404 BUSINESS PHONE: (310) 824-9999 MAIL ADDRESS: STREET 1: 2225 COLORADO AVENUE CITY: SANTA MONICA STATE: CA ZIP: 90404 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CHAMPSI FARAH CENTRAL INDEX KEY: 0001198321 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36508 FILM NUMBER: 17765839 MAIL ADDRESS: STREET 1: ONE EMBARCADERO CENTER SUITE 3700 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-04-13 0 0001510580 Kite Pharma, Inc. KITE 0001198321 CHAMPSI FARAH C/O KITE PHARMA, INC. 2225 COLORADO AVENUE SANTA MONICA CA 90404 1 0 0 0 Common Stock 2017-04-13 4 S 0 72275 82.39 D 191144 I See Footnote Common Stock 2017-04-17 4 S 0 43001 82.48 D 148143 I See Footnote Common Stock 2017-04-17 4 S 0 100 83.06 D 148043 I See Footnote Common Stock 79152 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.05 to $82.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Reflects the disposition by Alta Partners VIII, L.P. ("APVIII") of 1,500,000 shares of the Issuer's common stock in a pro-rata distribution to its limited partners on October 19, 2016. Also reflects the transfer from the reporting person to APVIII of 487 shares of the Issuer's common stock on January 26, 2017 and 975 shares of the Issuer's common stock on March 23, 2017. The reporting person has been awarded certain restricted stock units in her capacity as a director of the Company (the "RSUs"), and she is contractually obligated, as a managing director of APVIII, to transfer to APVIII, for no consideration, all shares of common stock that she receives upon the vesting of the RSUs. The securities are held of record by APVIII. Alta Partners Management VIII, LLC ("APMVIII") is the general partner of APVIII. The reporting person is a managing director of APMVIII and exercises shared voting and investment power with respect to the shares owned by APVIII. The reporting person disclaims beneficial ownership of such securities, except to the extent of her proportionate pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.05 to $83.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Includes 58,998 shares received in a pro-rata distribution from APVIII. In prior reports, the reporting person reported beneficial ownership of all shares of the Issuer's common stock held by APVIII. Also reflects the transfer from the reporting person to APVIII of 487 shares of the Issuer's common stock on January 26, 2017 and 975 shares of the Issuer's common stock on March 23, 2017. The reporting person has been awarded certain RSUs in her capacity as a director of the Company, and she is contractually obligated, as a managing director of APVIII, to transfer to APVIII, for no consideration, all shares of common stock that she receives upon the vesting of the RSUs. /s/ David M. Tanen, Attorney-in-Fact 2017-04-17